CEO Jay Flatley said that firm's sequencing revenues grew 80 percent over the first quarter of 2010, due in large part to broad adoption of the firm's HiSeq 2000.
Full-text access for registered users only.
Existing users login here
New to GenomeWeb? Register here
quickly for free access.